Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -12.12
- Piotroski Score 1.00
- Grade Buy
- Symbol (IMUX)
- Company Immunic, Inc.
- Price $1.11
- Changes Percentage (-5.13%)
- Change -$0.06
- Day Low $1.10
- Day High $1.18
- Year High $2.11
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $5.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.83
- Trailing P/E Ratio -0.67
- Forward P/E Ratio -0.67
- P/E Growth -0.67
- Net Income $-93,612,000
Income Statement
Quarterly
Annual
Latest News of IMUX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges
The earnings call discussed the upcoming detailed data release for the Caliber study in progressive MS, including subpopulation data like clinical endpoints and biomarkers. Data is expected in April n...
By Yahoo! Finance | 5 days ago
